Alkahest to Present at Alzheimer’s Association International Conference (AAIC) Annual Meeting July 22-26, 2018 Chicago, IL
July 23, 2018
Presentations highlight a novel multifactorial approach to the treatment of Alzheimer’s Disease
SAN CARLOS, Calif., — Alkahest Inc. (“Alkahest”), a clinical-stage biotechnology company focused on developing innovative therapies to treat Alzheimer’s Disease and other age-related diseases, today announced upcoming presentations at the Alzheimer’s Association International Conference in Chicago, July 22 to 26, 2018. The Alkahest team will present recent preclinical data and clinical trial designs for the company’s novel approaches to the treatment of Alzheimer’s Disease. Details for specific presentations are:
- Beneficial Properties of a Human Plasma Fraction for Age-Related Cognitive Disorders (Gallager, July 23, F1/P2-064)
- Rationale and Design of a Prospective, Randomized, Double-Blind, Dose-Comparison Safety and Tolerability Study of GRF6019 in Mild-to-Moderate Alzheimer’s Disease (Hannestad, July 23, F1/P2-029)
- Targeting the Eotaxin/CCR3 Pathway in Aging-Associated Cognitive Decline (Minami, July 24, F1/P3-043)
- CCR3 Antagonism Drives Neuroinflammatory Benefits in Aged Mice (Rege, July 24, F1/P3-051)
“These presentations and findings add to the growing body of research supporting our hypothesis that factors in the plasma proteome play an important modulatory role in age-related disease, particularly cognitive dysfunction and neurodegeneration. This presents an entirely new opportunity for therapeutic interventions,” said Karoly Nikolich, Ph.D., Chief Executive Officer of Alkahest. “As the world’s population grows older, the burden of age-related diseases will quickly become one of the greatest medical challenges of our generation. Our innovative therapeutics targeting the plasma proteome are currently in clinical development and are well-positioned to address this critical need,” said Jonas Hannestad, M.D., Ph.D., Alkahest’s Vice President, Clinical Development.
Alkahest is a privately-held clinical-stage company based in the San Francisco Bay Area developing treatments for age-related diseases, with an emphasis on neurodegeneration — a key medical challenge for our generation. The company’s breakthrough research has elucidated changes in the plasma proteome in healthy aging and age-related diseases, and demonstrated that factors in the blood plasma can be augmented or inhibited in order to reverse detrimental effects of aging in both normal aging and disease models in animals. Alkahest is developing novel plasma-based therapies in collaboration with Barcelona, Spain-based Grifols, a global healthcare company and leading producer of plasma therapies.
Vice President Business Development